Ther Adv Med Oncol 2022
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.
Related Questions
Role of PI3K inhibitors vs SERD? What factors help you decide?
New answer by Medical Oncologist at University of Wisconsin School of Medicine and Public Health (May 12, 2025)
As long as the patient had more than 12 months on the first-line CDK4/6i, I think both are reasonable options. This is an area which requires good discussion with the patient ...